Mark Weeks

Cooley represented Beta Bionics, a pioneering leader in the development of advanced diabetes management solutions, in its $234.6 million initial public offering and concurrent $17 million private placement.

Cooley advised Sword Health, pioneer of the AI Care platform, which uses artificial intelligence to power the delivery of care, on its raise of $130 million in a mix of primary and secondary sales.

Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering.

Cooley advised Procyrion, a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, on the close of its $57.7 million Series E financing, including the conversion of $10 million in interim financing.

Cooley advised Apollo Endosurgery, a medical device company, on its agreement to be acquired by Boston Scientific in an all-cash transaction with an enterprise value of approximately $615 million.